Kimberly-Clark to Acquire Kenvue for $40 Billion

Kimberly-Clark is acquiring Kenvue for $40 billion, raising concerns among investors due to Kenvue’s struggles with weak sales and legal issues related to Tylenol. Despite a 46% premium, Kimberly-Clark anticipates $2.1 billion in annual cost savings and increased revenue from Kenvue’s brand portfolio. The deal, influenced by activist pressure, is set to close in late 2026, with Kimberly-Clark’s CEO taking the helm. Kenvue shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held.